HerCan+-TEK™
Understanding your genetic risk is the first step in a personalized cancer prevention strategy. Virotek offers two levels of hereditary cancer screening to match the specific needs of your personal and family medical history.
Order TestWho is HerCan-TEK™ For?
Family History of Cancer
Breast, ovarian, colorectal, or other hereditary cancers in the family.
Early-Onset Cancers
Individuals diagnosed with cancer at a young age.
Multiple Primary Cancers
Patients with more than one primary cancer diagnosis.
Proactive Screening
Anyone seeking preventive cancer risk assessment.
Compare Test Levels
Choose the right level of cancer risk screening for your needs.
HerCan-TEK™ (Basic)
Genes analyzed (10): BRCA1, BRCA2, PALB2, ATM, CHEK2, TP53, MLH1, MSH2, MSH6, PMS2
Cancer scope: Population-based screening focused on the most common hereditary cancer risks, including breast, ovarian, and colorectal cancer.
HerCan-TEK+™ (Comprehensive)
Gene scope: 10 basic genes plus 67 others, such as APC, VHL, CDH1, PTEN, STK11, and more…
Cancer scope: Broader coverage for solid tumors and rare syndromes—including breast, ovarian, colorectal, prostate, pancreatic, gastric, renal, endocrine, melanoma, and other hereditary cancers.
Clinical Utility & Implementation Tips
Virotek panels are designed to integrate seamlessly into oncology and primary care workflows.
Tiered Testing Strategy: Use HerCan-TEK™ as an efficient option for standard cases and escalate to HerCan+-TEK™ for complex or multi-system family histories.
Actionable Management: Use results to guide preventive surgical decisions, initiate high-risk surveillance protocols (e.g., breast MRI), or inform the use of targeted therapies like PARP inhibitors.
How It Works
A simple, guided process from consultation to clinically actionable reporting.
Ready to Integrate HerCan-TEK™ Into Your Practice?
Contact our team to learn how our tests can enhance your clinical offerings and improve patient outcomes.
Contact Sales Request Information